Role of maximum androgen blockade in advanced prostate cancer

Rajinikanth Ayyathurai, Rosely Santos, Murugesan Manoharan

Research output: Contribution to journalReview article

1 Scopus citations


Androgen ablation is the mainstay treatment for advanced prostate cancer (PC). Researchers proposed that maximum androgen blockade (MAB) therapy with antiandrogen agent in combination with castration might result in a better outcome among patients with advanced PC. In the last two decades, numerous trials and pooled data analyses were conducted to optimize the role of MAB in the treatment of metastatic PC. Non-steroidal antiandrogens administered as part of MAB proved to have a small (3%) survival benefit, however, the magnitude of this difference is of questionable clinical significance. Available evidence suggests that MAB should not be routinely offered to patients with metastatic PC, however, it should remain a reasonable option when discussing management. The standard first line treatment should be a monotherapy, consisting of orchiectomy or LHRH agonist. MAB still has a role as a short-term therapy (2-4 weeks). The ongoing large sample population based prospective studies may add new dimensions in the use of MAB in treatment of the prostate cancer in future.

Original languageEnglish (US)
Pages (from-to)47-51
Number of pages5
JournalIndian Journal of Urology
Issue number1
StatePublished - Jan 1 2009


  • Advanced prostate cancer
  • Maximum androgen blockade
  • Total androgen blockade

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Role of maximum androgen blockade in advanced prostate cancer'. Together they form a unique fingerprint.

Cite this